- Home
- NHI vs ARQT Comparison
NHI vs ARQT Comparison
Compare NHI & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NHI | ARQT |
|---|---|---|
| Founded | 1991 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.3B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NHI | ARQT |
|---|---|---|
| Price | $77.47 | $20.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $87.00 | $34.00 |
| AVG Volume (30 Days) | 411.0K | ★ 1.8M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 0.82 | N/A |
| Revenue | $375,628,000.00 | ★ $376,072,000.00 |
| Revenue This Year | $15.44 | $34.85 |
| Revenue Next Year | $10.01 | $29.39 |
| P/E Ratio | $93.27 | ★ N/A |
| Revenue Growth | 12.07 | ★ 91.34 |
| 52 Week Low | $68.80 | $12.72 |
| 52 Week High | $91.38 | $31.77 |
Technical Indicators
Market Signals| Indicator | NHI | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 39.63 |
| Support Level | $76.15 | $19.60 |
| Resistance Level | $77.98 | $24.56 |
| Average True Range (ATR) | 1.85 | 1.27 |
| MACD | 0.54 | -0.20 |
| Stochastic Oscillator | 95.82 | 23.32 |
Price Performance
Historical ComparisonAbout NHI National Health Investors Inc.
National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.